Policy | August 16, 2021
India restricts export of Rapid Antigen Test Kits used to detect Covid 19
The notification implies that any export of Rapid Antigen Kit will require a licence or permission from DGFT
The notification implies that any export of Rapid Antigen Kit will require a licence or permission from DGFT
Filing for WHO Emergency Use Authorisation this month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
CDSCO to fast-track trials and approval for COVID19 vaccine
Arch Pharma Labs has filed the application
The govt has rolled out three schemes for promoting the manufacture of API
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Subscribe To Our Newsletter & Stay Updated
